| Common Brands | Aralast NP |
|---|---|
|
Drug Class |
Alpha-1 Antitrypsin Replacement Therapy |
|
Controlled Substance Classification |
Not a controlled medication |
|
Generic Status |
Lower-cost generic available |
|
Availability |
Prescription only |
Aralast NP is a drug to treat alpha-1 antitrypsin deficiency, which is a genetic disorder and leads to the diseases in lungs and livers. Aralast NP is a purified human alpha-1 antitrypsin (AAT) that helps protect the lung from the damaging effects of neutrophil elastase, an enzyme that may break down lung tissue. In alpha-1 antitrypsin deficiency, the lung and liver damage that follows results from the inadequate level of this protective protein; emphysema most commonly.
Aralast NP is used as replacement therapy to replace deficient alpha-1 antitrypsin levels and assist in slowing the progression of lung and liver damage that results in alpha-1 antitrypsin deficiency.
Aralast NP is administered as an intravenous (IV) infusion. A healthcare professional will prepare the medication to ensure it is mixed and diluted appropriately before injection.
Preparation: The Aralast NP vial is reconstituted with sterile water, and the solution is then prepared for infusion.
Administration: Aralast NP is typically administered once a week. The patient will receive the infusion in a clinical setting or at home if the healthcare provider approves home infusion.
Monitoring: The patient will be monitored for immediate allergic reactions and side effects during infusion. Infusions are relatively tolerated; however, in some cases, patients do report symptoms of fever and chills.
Patients should adhere to the prescribed regimen and regularly come for follow-up to ensure that the drug is not causing any adverse reactions. The infusion schedule or the dose can be altered depending on the patient’s response and any side effects he or she may experience.
Aralast NP works by replacing the deficient alpha-1 antitrypsin protein in AATD patients. This protein produced by the liver is transported into the blood stream wherein it exerts its action. In the healthy organism, alpha-1 antitrypsin prevents the action of enzymes, for instance, neutrophil elastase, from causing any damage to lung tissue.
In individuals with AATD, neutrophil elastase does not have sufficient alpha-1 antitrypsin to inhibit it properly. This results in an unchecked neutrophil elastase that destroys lung tissue and leads to emphysema or other types of lung diseases. Since this drug delivers a purified version of this protein, Aralast NP prevents further deterioration of the lungs, slow the progression of emphysema, and hence decrease the use of supplementary treatment, such as bronchodilators or inhaled steroids.
The protein provided by Aralast NP also reduces inflammation and can have a protective effect on the liver, which is particularly important for individuals who are at risk of liver disease due to AATD.
Common side effects of Aralast NP may include:
Infusion-related reactions: These involve fever, chills, rash, and nausea, which usually resolve after infusions are completed. Such patients may need medical evaluation if the reaction is particularly severe.
Allergic reaction: This is a rather rare occurrence but can develop as hives, shortness of breath, or swelling for some patients. Such symptoms should be evaluated immediately to avoid further complications.
Other side effects: Some patients may suffer from joint pains, fatigue, or even mild respiratory symptoms. The side effects are usually mild and temporary.
Serious side effects are rare and include:
Anaphylactic reaction: This is a severe allergic reaction that requires immediate medical attention.
Hepatic complications: Although this is rare, some patients may suffer from liver problems due to the infusion therapy.
Allergic Reactions: Patients have to be kept under a close watch for any symptoms of allergic reaction to the Aralast NP through and after infusion. Special care may have to be taken for the patient that has had some history of severe allergic reaction to an intravenous therapy.
Infusion Reactions: Health care should keep the patient under regular observation while infusion is made. Some infusion reactions experienced are fever, chills, or even hives, though it is minimal.
Liver Disease: Patients with existing liver conditions should be closely monitored, as alpha-1 antitrypsin deficiency itself can cause liver damage, and Aralast NP may exacerbate this in some individuals.
Pregnancy and Breastfeeding: The safety of Aralast NP during pregnancy and breastfeeding has not been fully established. It is important for pregnant or breastfeeding women to discuss the risks and benefits with their healthcare provider before starting treatment.
Since Aralast NP is a replacement therapy for a protein in the body, it is unlikely to interact with most drugs. However, as with any infusion therapy, patients receiving Aralast NP should be monitored for potential allergic reactions or infusion-related side effects.
There are no known major drug-drug interactions with Aralast NP; however, all medications the patient is taking should be brought to the attention of the healthcare provider, including over-the-counter drugs and supplements.
The standard dose of Aralast NP is based on the patient’s weight. The average dose is 60 mg/kg body weight, and it is administered once a week via intravenous infusion. The healthcare provider can adjust the dosing regimen based on the clinical response of the patient and side effects experienced. Follow-up visits are necessary to monitor the condition of the patient and see if changes are required.
Aralast NP can only be prescribed, thus a healthcare provider should possess experience in the treatment and management of alpha-1 antitrypsin deficiency. A health professional will assess the clinical status of the patient to know the appropriate dosing regimen. Patients on Aralast NP will also require constant assessment and follow-up appointments so that the effectiveness of their treatment and any possible adverse effects can be reviewed.
What is Aralast NP?
How does Aralast NP work?
What conditions is Aralast NP used to treat?
Who is a candidate for Aralast NP treatment?
How is Aralast NP administered?
What are the common side effects of Aralast NP?
Are there any serious risks associated with Aralast NP?
Can Aralast NP be used during pregnancy?
How often do patients need to receive Aralast NP?
Is there any special monitoring required while on Aralast NP?
Can Aralast NP be used in children?
What should I do if I miss a dose of Aralast NP?
Can I take other medications while on Aralast NP?
How should Aralast NP be stored?
What happens if Aralast NP is not refrigerated?
What are the signs of an allergic reaction to Aralast NP?
Can Aralast NP be used long-term?
What should I do if I experience an infusion reaction?
Is there a risk of developing infections from Aralast NP?
Where can I find more information about Aralast NP?
Seborrheic dermatitis is a widespread chronic inflammatory skin disorder that primarily affects the head, scalp, and upper trunk, which are areas rich in sebaceous glands. Despite not being a fatal illness, the chronic nature of the disorder and its frequent flare-ups can greatly lower the person’s standard of life. The goal of this thorough investigation
For a considerable time, both scientists and medical experts have been fascinated by the connection between the gastrointestinal tract and the brain. The gut-brain axis is a concept that has emerged from emerging research that highlights the deep relationship between both of these seemingly different organs. We will explore the elements, functions, and consequences associated
Food intolerances are becoming more widely acknowledged as serious health issues impacting people all over the world. In contrast to food allergies, which are immune system-related, food intolerances usually refer to the body’s incapacity to properly digest specific substances or dietary ingredients. This thorough review explores several kinds of food intolerances, such as fructose malabsorption,
